Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages

  Van Lierop, A H ^a   Van Der Eerden, A W ^b   Hamdy, N A T ^a   Hermus, A R ^b   Den Heijer, M ^b   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CARBOXY TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; FIBROBLAST GROWTH FACTOR 23; HYDROCORTISONE; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; SCLEROSTIN; UNCLASSIFIED DRUG;

ADRENALECTOMY; ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOGENOUS HYPERCORTISOLISM; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; TRANSSPHENOIDAL SURGERY;

ADRENALECTOMY; ADULT; ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; COLLAGEN TYPE I; CUSHING SYNDROME; FEMALE; FIBROBLAST GROWTH FACTORS; GENETIC MARKERS; HUMANS; HYDROCORTISONE; MALE; MICE; MIDDLE AGED; OSTEOCYTES; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 84867275947     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2218     Document Type: Article

References (20)

1. Weinstein RS 2001 Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2:65-73 (Pubitemid 33643893)
2. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocor-ticoid- induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328 (Pubitemid 47389469)
3. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE 2008 Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58:1674-1686 (Pubitemid 351847520)
4. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R 2005 Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177-181 (Pubitemid 40255437)
5. Humphrey EL, Williams JH, Davie MW, Marshall MJ 2006 Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38:652-661
6. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of gluco-corticoid-induced osteoporosis. Endocrinology 140:4382-4389 (Pubitemid 30666099)
7. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK 2011 Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385-2395
8. Hardy R, Cooper MS 2009 Bone loss in inflammatory disorders. J Endocrinol 201:309-320
9. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ 2009 Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen-activated protein kinase (MAPK)- dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24:1434-1449
10. Netea-Maier RT, van Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG, Grotenhuis JA, Hermus AR 2006 Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol 154:675-684 (Pubitemid 43810853)
11. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE 2011 Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26:2804-2811
12. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R 2011 Determination of serum and plasma sclerostin concentrations by enzymelinked immunoassays. J Clin Endocrinol Metab 96:E1159-E1162
13. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814 (Pubitemid 38375200)
14. Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, Biswas SK, Lo WK, Jiang JX 2010 Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 25:2479-2488
15. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC 2011 Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 286:44326-44335
16. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000 (Pubitemid 30350061)
17. Manolagas SC, Weinstein RS 1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061-1066 (Pubitemid 29314048)
18. van Lierop AH, Hamdy NA, Papapoulos SE 2010 Glucocorticoids are not always deleterious for bone. J Bone Miner Res 25:2796-2800
19. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ 2011 Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway. PLoS One 6:e25900
20. Weinstein RS, O'Brien CA, Almeida M, Zhao H, Roberson PK, Jilka RL, Manolagas SC 2011 Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152: 3323-3331